Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
Clinical trial NCT02574533 · COMPLETED
Trial details
- NCT number
- NCT02574533
- Sponsor
- Gradalis, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-10-01
- Primary completion
- 2017-09-01
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.